<table>
<thead>
<tr>
<th>Title</th>
<th>Using electrical stimulation to enhance the efficacy of cell transplantation therapies for neurodegenerative retinal diseases: Concepts, challenges, and future perspectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Manthey, AL; Liu, W; Jiang, Z; Lee, MHK; Jian, J; So, KF; Lai, JSM; Lee, WHV; Chiu, K</td>
</tr>
<tr>
<td>Citation</td>
<td>Cell Transplantation, 2017, v. 26, p. 949-965</td>
</tr>
<tr>
<td>Issued Date</td>
<td>2017</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10722/242918">http://hdl.handle.net/10722/242918</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
Review

Using Electrical Stimulation to Enhance the Efficacy of Cell Transplantation Therapies for Neurodegenerative Retinal Diseases: Concepts, Challenges, and Future Perspectives

Abby Leigh Manthey,* Wei Liu,† Zhi Xin Jiang,* Marcus Hiu Kong Lee,* Jian Ji,† Kwok-Fai So,*§ Jimmy Shiu Ming Lai,*§ Vincent Wing Hong Lee,* and Kin Chiu*‡§

*Department of Ophthalmology, The University of Hong Kong, Hong Kong SAR, P.R. China
†Tianjin Medical University Eye Hospital, Tianjin, P.R. China
‡Research Centre of Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong, Hong Kong SAR, P.R. China
§State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong SAR, P.R. China
¶GHM Institute of CNS Regeneration, Jinan University, Guangzhou, P.R. China

Disease or trauma-induced loss or dysfunction of neurons in any central nervous system (CNS) tissue will have a significant impact on the health of the affected patient. The retina is a multilayered tissue that originates from the neuroectoderm, much like the brain and spinal cord. While sight is not required for life, neurodegeneration-related loss of vision not only affects the quality of life for the patient but also has societal implications in terms of health care expenditure. Thus, it is essential to develop effective strategies to repair the retina and prevent disease symptoms. To address this need, multiple techniques have been investigated for their efficacy in treating retinal degeneration. Recent advances in cell transplantation (CT) techniques in preclinical, animal, and in vitro culture studies, including further evaluation of endogenous retinal stem cells and the differentiation of exogenous adult stem cells into various retinal cell types, suggest that this may be the most appropriate option to replace lost retinal neurons. Unfortunately, the various limitations of CT, such as immune rejection or aberrant cell behavior, have largely prevented this technique from becoming a widely used clinical treatment option. In parallel with the advances in CT methodology, the use of electrical stimulation (ES) to treat retinal degeneration has also been recently evaluated with promising results. In this review, we propose that ES could be used to enhance CT therapy, whereby electrical impulses can be applied to the retina to control both native and transplanted stem cell behavior/survival in order to circumvent the limitations associated with retinal CT. To highlight the benefits of this dual treatment, we have briefly outlined the recent developments and limitations of CT with regard to its use in the ocular environment, followed by a brief description of retinal ES, as well as described their combined use in other CNS tissues.

Key words: Neurodegeneration; Retina; Electrical stimulation (ES); Combination therapy

INTRODUCTION

The vast majority of cells in the human body are programmed to perform specialized functions, having unique morphological, functional, and electrical properties. This is also true for cells in the ocular environment, including those of the retina. The mammalian retina contains five groups of neurons responsible for transmitting light signals to the brain: photoreceptor cells (cones and rods), bipolar cells, horizontal cells, amacrine cells, and retinal ganglion cells (RGCs). These cells are supported by the Müller cells, which are the primary immune cells in the retinal environment along with retinal microglia. Furthermore, the retinal pigmented epithelium (RPE), a monolayer of cells located between the photoreceptor cells and Bruch’s membrane, forms the blood–retinal barrier in addition to metabolically supporting other processes.
including phagocytosis of photoreceptor outer segments and secretion of various trophic factors\(^1\). During disease or following traumatic injury, any number of these specialized cells of the retina can be damaged or lost, resulting in varying levels of retinal degeneration and decreased visual acuity.

Although the mechanisms underlying retinal degeneration are distinct for each disease, they invariably involve the irreversible loss of retinal neurons, neuronal connections, and/or supporting glia\(^2\). For example, glaucoma involves the selective loss of RGCs, while photoreceptor loss is common during retinitis pigmentosa (RP)\(^3\). Age-related macular degeneration (AMD), on the other hand, involves degeneration of the RPE as well as photoreceptor cell death\(^4\). To date, there are currently no singularly reliable clinical treatment options to completely halt or reverse the loss of vision associated with these diseases. However, a number of novel techniques are currently being evaluated for their potential therapeutic use in the treatment of retinal degeneration, including gene therapy, optogenetics, electrical stimulation (ES), cell transplantation (CT), etc.

In this review, we have focused on the treatment of several prominent retinal diseases, including AMD, RP, traumatic optic neuropathy (TON), nonarterial ischemic optic neuropathy (NAION), and retinal artery occlusion (RAO). Basic descriptions of these diseases can be found in Figure 1. Once neuronal degradation has occurred, it is essential that these cells and synaptic connections be replaced in order to restore vision to the patient, making CT one of the most attractive treatment options. However, the application of CT methods in the retina comes with a number of limitations. Thus, we hypothesize that a dual therapeutic approach should be adopted utilizing ES to augment CT to treat retinal degeneration. While this theory has never been tested in the retina, it is supported by various studies in other tissues, highlighting the additive benefits of the two techniques, whereby CT can be used to replace lost cells and/or provide trophic support, while ES can be utilized to stimulate and protect the remaining endogenous cells in addition to facilitating function in the transplanted cells. Together, we believe these treatments provide the highest possibility for improvement in visual acuity.

**Age-related macular degeneration (AMD)**
AMD, the leading cause of blindness in individuals older than 65 years of age in the industrialized world, is a degenerative condition that begins in Bruch's membrane and progresses to involve the retinal pigmented epithelium (RPE) as well as the overlying photoreceptors. Further, in order to study the end-point morphology of human AMD, light-induced retinal damage, which causes similar defects as those observed during advanced atrophic AMD, has been used in various rodent models.

**Retinal artery occlusion (RAO)**
RAO, as an ophthalmic emergency, usually leads to sudden, painless, permanent vision loss, and the retinal damage progresses very quickly. There are two clinically distinct types of RAO: central RAO (CRAO), which is typically associated with poor visual prognosis, and branch RAO (BRAO), which often has a relatively good visual prognosis if intervention is initiated rapidly and the fovea is not involved. There are several methods currently used to treat RAO, such as ocular massage, hyperbaric oxygenation, intraocular pressure lowering by anterior chamber paracentesis or medications, intravenous injection of urokinase, etc. However, there is not a standard, reliable treatment option that is universally effective during the critical period of vision improvement for RAO patients. Therefore, the majority of RAO patients, especially CRAO patients, will suffer from significant visual loss and retinal damage. RAO animal models, whereby the intraocular pressure is raised for a period of time to induce ischemia, are the primary means used to study this disease.

**Non-arteritic ischemic optic neuropathy (NAION)**
Ischemic optic neuropathy is one of the major causes of blindness or seriously impaired vision among the middle-aged and elderly population. Ischemic optic neuropathy can be divided into two types: anterior ischemic optic neuropathy (AION) and posterior ischemic optic neuropathy, with the primary type being AION. AION consists of two etiologically different subgroups: anterior AION and non-arteritic AION (NAION). A number of methods have been advocated to treat NAION, including optic nerve sheath decompression, aspirin treatment, systemic corticosteroid treatment, intravitreal triamcinolone acetonide, intravitreal bevacizumab, reduction of risk factors, etc. However, the management of NAION still remains controversial. Rodent models of NAION, involving the injection of rose Bengal into the tail vein followed by photoactivation of the optic nerve using a laser, have been used to study disease pathogenesis.

**Traumatic optic neuropathy (TON)**
TON involves acute injury to the optic nerve that disrupts visual function. The treatment of TON is controversial. For example, the role of intravenous methylprednisolone versus conservative management is often debated, and the role of optic canal decompression is also not conclusive at present. Currently, there are two primary animal models used to study the effects of ES treatment on TON: optic nerve crush and optic nerve transection (axotomy). During the optic nerve crush procedure, the optic nerve of a rat is exposed and crushed without damaging the retinal blood flow, while transection involves the full severing of the nerve.

**Retinitis pigmentosa (RP)**
RP is an inherited degenerative disease of the retina leading to the progressive loss of peripheral vision and subsequent loss of central vision. RP is exceptionally heterogeneous, involving not only genetic heterogeneity, but also allelic, phenotypic, and clinical heterogeneity. Several different animal models of RP have been utilized in previous studies, including rhodopsin P347L transgenic rabbits and Royal College of Surgeons (RCS) rats, which have a defect in the merTK gene that results in abnormal phagocytosis of the photoreceptor outer segments.

**Figure 1.** General descriptions of various retinal degenerative diseases, including age-related macular degeneration (AMD), retinitis pigmentosa (RP), traumatic optic neuropathy (TON), nonarterial ischemic optic neuropathy (NAION), and retinal artery occlusion (RAO).
acuity following retinal degeneration or trauma. In this review, we begin our analysis by first discussing current CT techniques and their limitations along with a brief history of ES, followed by an evaluation of their combined therapy in other tissues emphasizing the potential applications in the retina.

**EVALUATION OF CURRENT RETINAL CELL TRANSPLANTATION METHODOLOGIES**

CT involves the replacement of dead or abnormal cells with healthy cells that mimic their normal function and behavior. Thus, in retinal degenerative diseases, cells must be replaced with the specific cell type lost, namely, the photoreceptor cells, RPE, and/or RGCs. While transplantation of sheets or suspensions/aggregates of retinal cells is feasible to some extent, the level of integration of these cells appears to be largely dependent on the age of the donor/host, quality of the transplanted cells, and the type of retinal degradation involved, as highlighted by experiments performed in various disease models5–21, thus limiting their effectiveness. Further, developing fetal retinal cells have also been investigated for their use in retinal CT techniques with some success5. However, a large quantity of these postmitotic cells is required, the collection of which also poses ethical issues. In fact, many research groups have turned to use of adult stem cells in clinical and laboratory settings in order to avoid these ethical concerns and enhance the level of cellular integration into the retina.

Stem cells are cells that have the potential to develop into many other cell types and can be used to replace cells that are lost, damaged, or altered during disease or trauma. Although the term “stem cell” has been used variably since 1906 when Alexander Maximow developed his theory of hematopoiesis22,23, it was not until 1981 that murine embryonic stem cells (ESCs) were isolated24,25. Further, it was another 17 years before Thomson et al.26 isolated human ESCs and developed the first human embryonic culture stem cell lines. Since their discovery, researchers worldwide have sought to understand stem cell behavior, morphology, and function. Notably, the three essential characteristics of these cells are that they are unspecialized, self-renewing, and potent. The level of stem cell potency, or the range of cell types they can differentiate into, may vary depending on the age of the organism at isolation. For example, totipotent stem cells, which can differentiate into all cell types found in both embryonic and extraembryonic tissues, are typically derived from cells in the first 4 days following fertilization of the egg in mammals (up to approximately the 16-cell stage), while pluripotent (giving rise to all embryonic cell types) and multipotent stem cells (giving rise to cells of a specific germ layer) can be found later in development as well as in some adult tissues, including the eye27.

**Endogenous Retinal Stem Cells for Transplantation**

The retina develops from the neural tube and, while morphologically unique, is classified as a central nervous system (CNS) tissue. Although somatic stem cells are present in most tissues, being largely found in clusters known as niches, endogenous adult retinal stem cells have been difficult to identify. A large proportion of the ocular regeneration literature is focused on fish and amphibian models26–30, which utilize a type of intrinsic retinal regeneration that does not occur in mammals. However, these studies have led to the identification of three primary types of endogenous adult retinal cells that have been evaluated for transplantation in various species: Müller cells31–38, RPE cells39,40, and ciliary pigmented epithelial (CPE) cells41–44 (Fig. 2A). While there is some controversy as to the specific stem cell nature of these cells44,45, there is evidence indicating that they can differentiate into retinal cell types under certain conditions. In fact, Müller cells appear to primarily differentiate into cone and rod photoreceptors46–48 as well as RGCs27, while CPE and RPE cells have the potential to differentiate into rod or cone photoreceptor-like cells, respectively45,49–54. During the transplantation/retinal regeneration process, these cell types would need to undergo several cellular actions, including dedifferentiation, proliferation, migration, neural differentiation, and functional integration55. Interestingly, subretinal or intravitreal injection of Müller cells derived from humans leads to migration of the transplanted cells into the retinal parenchyma and expression of neuronal cell markers31, while transplantation of CPE or RPE cells has been performed with varying levels of success56.

Notably, the use of CPE or similar progenitor cells in the ins45–48 could, in theory, be isolated from the affected patient, limiting issues with immune rejection. However, caution should be exercised if the patient’s particular retinal disease has a genetic component. In contrast, autologous CT using Müller glia from the patient’s retina is not feasible, necessitating the use of donor cells57. Preparation and transplantation of postmitotic RPE cells or sheets from a donor, while possible, involve a significant amount of tissue and may also be associated with a higher level of surgical risk55. To circumvent these issues, recent research has described methodologies using non-retinal stem cell-derived RPE cells, photoreceptors, and RGCs that may, in some aspects, provide additional advantages over endogenous ocular cells, such as lowering the chances of immune rejection and providing an unlimited number of donor cells52–57.

**Exogenous Stem Cells for Retinal Transplantation**

Various types of nonretinal stem cells have been studied for their use in retinal CT (Fig. 2B). This includes neural stem cells (NSCs), which have been employed for neural
and glial cell replacement in spinal cord and brain injuries, and function to protect the photoreceptors in the damaged retina via their phagocytic capabilities to eliminate the photoreceptor outer segments—a role typically performed by the RPE—and the secretion of neurotrophic factors. Mesenchymal stem cells (MSCs), which can be derived from bone marrow (BM-MSCs), adipose tissue (ADSCs), or dental pulp (DPSCs), appear to play a trophic support role via the secretion of factors that stimulate endogenous cells. Finally, ESCs, from the inner cell mass of the blastocyst, and induced pluripotent stem cells (iPSCs), which can be reprogrammed from adult fibroblasts and somatic cells via retroviral transduction, have been used to replace photoreceptor cells, RPE cells, and all other cells of the retina.

Recent research suggests that in order to increase integration and function of retinal cells derived from nonretinal stem cells, regardless of origin, they should first be differentiated in vitro prior to transplantation. For example, have been observed to differentiate into both RPE cells and photoreceptors when cocultured with RPE cells in vitro, but show no evidence of differentiation into mature retinal cells after direct transplantation despite integration into the retina. Thus, it seems that while BM-MSCs may play a neuroprotective role when transplanted, differentiation into retinal cell types before transplantation is essential if these cells are being used to replace the lost or abnormal cells. Interestingly, human ESCs can be differentiated into retinal cells in serum-free culture media supplemented with a mixture of noggin, dickkopf-related protein 1 (DKK-1), insulin-like growth factor 1 (IGF-1), and basic fibroblast growth factor (bFGF). Similar techniques also work for iPSCs using specific combinations of growth factors. Differentiation into retinal neurons was also enhanced when cocultured with mouse retinas from photoreceptor-degenerated mice. For a full review of ESC/iPSC reprogramming and retinal differentiation/transplantation protocols, please see Reynolds and Lamba, Borooah et al., and Wright et al.

Importantly, the transcriptome/proteome of these cells should ideally mimic that of the native cells they are replacing. In doing so, the likelihood of these cells interacting appropriately with the neighboring healthy cells may increase. To this end, Lamba and Reh have published genomic profiling data comparing human ESC-derived retinal cells to fetal human retinal cells and showed that the expression of retinal genes between the two subsets of cells are strongly correlated. Thus, it appears that these ESC-derived cells adopt similar gene expression as that utilized during retinal development. iPSCs, on the other hand, have their own distinct expression profile, highlighting some potential differences. However, regardless of gene expression, the transplanted cells ultimately need to behave as the native cells would. This includes integrating into the correct retinal layer and forming functional synapses, which are essential to improving visual acuity. This has been shown to occur when using human ESC-derived retinal cells following subretinal transplantation in adult wild-type mice, whereby the transplanted photoreceptor cells migrated into the outer nuclear layer and extended outer segments. In this same study, there was also evidence of neuroprotection on the surrounding host cells when transplanted into a light-damage model as well as functional responses to light using electroretinography (ERG) after transplantation in blind Crx−/− mice, which display photoreceptor degeneration. iPSC-derived photoreceptor cells transplanted into the subretinal space also integrated into the correct retinal layer and increased visual function.

While further research is necessary to determine the optimal transplantation conditions, the use of CT to treat retinal degenerative diseases, using endogenous or exogenous stem cells, is an interesting avenue of regenerative medicine. Notably, a number of clinical trials, as previously highlighted by Mead et al., and animal studies using exogenous stem cells to treat retinal diseases are ongoing.

Limitations of Cell Transplantation-Based Retinal Therapies

Although various cell types have been tried for retinal CT, very few have had reliable success. Furthermore, the methods and analyses used in retinal CT studies are often variable and require optimization. The limitations of each cell type, whether endogenous or exogenous, as

**Facing Page**

Figure 2. Cell transplantation cell types and basic approaches. (A) Endogenous retinal stem cells: Müller cells, retinal pigmented epithelial (RPE) cells, and ciliary pigmented epithelial (CPE) cells. Following transplantation, Müller cells have been shown to differentiate into both rod and cone photoreceptors as well as retinal ganglion cells (RGCs), while RPE and CPE cells differentiate into cone and rod photoreceptors, respectively. (B) Exogenous retinal stem cells: neural stem cells (NSCs; isolated from the brain), mesenchymal stem cells (MSCs; isolated from bone marrow, adipose tissue, and dental pulp), embryonic stem cells (ESCs; isolated from the inner cell mass at the blastocyst stage), and induced pluripotent stem cells (iPSCs; isolated adult fibroblasts/somatic cells that are reprogrammed using retroviral transduction). Stem cells are isolated and cultured in vitro. While these multipotent/pluripotent cells have been directly transplanted into the eye, higher levels of integration and functional restoration have been observed when the cells are differentiated into a retinal cell type prior to transplantation. This is particularly important if the stem cells are being used to replace degraded photoreceptors, RGCs, or RPE cells. The image of the hematoxylin and eosin-stained mouse eye was obtained using a light microscope (Carl Zeiss, Jena, Germany) using a 10× objective.
well as the quality of these cells before transfer also need to be weighed when determining what cell type and transplantation method (e.g., intravitreal injection, subretinal transplantation) to apply. In terms of results, ESCs seem to be a feasible option for retinal CT; however, the ethical issues surrounding their isolation hinder their clinical use. Thus, the use of differentiated iPSCs may be the most advantageous nonretinal donor source for CT to replace neurons following retinal degeneration as well as for disease modeling, testing therapeutic efficacy, and drug discovery.

An additional limitation to consider when assessing the cell type for retinal CT is the possible effects of using autologous stem cells from a subject with a genetic retinal disease. While using cells from the patient may limit immune system-related complications, it may also be necessary to “correct” the genetic defects in the cells prior to transplantation or risk the possible reoccurrence of the disease. This type of genetic correction has been performed previously to repair the mutation responsible for gyrate atrophy, which affects the RPE and leads to photoreceptor cell loss. However, the cost and effort required to produce and test gene-corrected cells are currently high. Alternatively, donor stem cells with a similar human leukocyte antigen (HLA) type can be used.

In some diseases involving multiple genetic risk factors and/or cellular aging specific to retinal tissue (e.g., AMD), it may be unnecessary to correct these genetic defects as the reprogramming process may restore a level of cellular youth.

Other limitations concerning the use of retinal CT stem from the plasticity of the transplanted cells (including the level of differentiation prior to and/or after transplantation) as well as the habitability of the host environment. For example, in the ocular environment, while Müller cell proliferation is required during retinal regeneration, this process of reactive gliosis can also result in scar tissue formation that may hinder integration of the transplanted cells. To circumvent this issue, it is possible to disrupt the outer limiting membrane formed by the activated Müller cells in order to increase cellular integration following transplantation. Indeed, West et al. demonstrated that immune suppression (using cyclosporine A treatment to reduce the T-cell-mediated immune response) increased the number of transplanted photoreceptor cells from 76 ± 20 cells per eye in the unsuppressed animals to 275 ± 89 cells per eye at 4 months posttransplantation, highlighting a significant change in the long-term survival of these cells. However, it would be ideal to avoid the need for pharmacological disruption of the already fragile diseased retina.

Furthermore, cell death-induced activation of retinal microglia is another common feature observed in genetic models of various retinal diseases as well as injury-induced retinal degeneration, and this activation may lead to the secretion of various cytokines and neurotoxins that can further injure the surrounding neurons. Protection of the retinal neurons appears to be largely modulated by the expression of neurotrophic growth factors secreted by microglia/Müller cells, such as IGF-1, ciliary neurotrophic factor (CNTF), etc., many of which appear to be altered after injury.

Although the eye, including the subretinal space, is considered an immune-privileged site, when ocular integrity is compromised, macrophage invasion and immune activation can result in rejection of the transplanted cells. Furthermore, it is currently unclear if an internal retinal microglial-mediated inflammatory response could act to hinder integration or function of the transplanted cells. These issues with immune rejection are common following CT in a number of tissues. In fact, it is important to avoid xenogenic factors (including animal serum, pathogens, and non-human-derived reagents) during culture and differentiation that may cause immune rejection after transplantation. While a chemical-based culture system as well as animal serum/contamination-free culture conditions have been implemented for generating retinal cells from human ESCs and iPSCs, immune rejection still poses a significant issue during retinal CT. Even if the process is successful and the cells are not rejected by the host, there are limited data indicating that the transplanted cells establish the functional synapses required for the restoration of visual function. Notably, recent literature has suggested that a more habitable native cell environment, allowing the transplanted cells to integrate and form synapses, can be facilitated using ES.

**HISTORY AND TYPES OF ELECTRICAL STIMULATION IN THE RETINA**

ES is a technique that uses an electrical current to activate nerves and restore function. Recent applications of ES in the field of neuroscience include both high-intensity and low-intensity ES currents, otherwise known as “functional ES,” and have been used to treat Parkinson's disease and other neurodegenerative diseases. Historically, the application of ES can be traced to 1791, when Galvani discovered that the leg muscles of a dead frog twitched when treated with an electrical spark. In ophthalmology, ES has a long history dating back as early as 1873, when Dor used complicated machines to treat “amblyopia and amauroses,” “retinochoroiditis with pigment infiltration,” and “glaucoma and white optic atrophy.” Furthermore, during normal ocular development, electrical waves are transmitted across the retina via neuronal action potentials. A study in 2002 by Morimoto et al., which demonstrated improved survival of transected RGCs in rats following ES, appears to be the first report that ES can mediate neuroprotection.
Since then, various studies have been performed to further evaluate the neuroprotective effect of ES both in vitro and in vivo, using cell culture, human trials, and animal models. Please see Sehic et al.\textsuperscript{118} for an excellent review of the most recent animal and clinical studies using ES.

**Types of Ocular Electrical Stimulation**

There are four types of ES commonly used in ophthalmology: subretinal ES (SES), optic nerve stump ES, transcorneal ES (TcES), and whole-eye ES (WES) (Fig. 3). In SES, a microphotodiode array is implanted in the subretinal space, and stimulation is applied directly to the retina. This type of ES has been widely used with retinal implants, which provide the patient with low-resolution images by stimulating the surviving retinal cells\textsuperscript{119,120}.

Alternatively, ES of the optic nerve stump uses a pair of electrodes attached to the end of the nerve to stimulate function, while TcES utilizes a contact lens containing both the active and reference electrodes directly on the cornea, making it much less invasive. WES generates an electrical current that goes through the entire eye, whereby one electrode is placed at either the cornea or the orbit, while the reference electrode is placed on the skin, in the mouth, or elsewhere in the body. The electrical current then passes through other tissues before reaching and stimulating the retina. Thus, the intensity may need to be higher for WES compared to other types of ES that come in direct contact with the ocular environment. WES includes techniques such as transorbital ES and transcranial alternating current stimulation (tACS).

![Figure 3](image-url)
A number of studies have been conducted utilizing these various types of ES, with TcES currently being the most common\(^{118}\).

Notably, while the published ES studies discussed in the present review primarily focus on stimulation of endogenous retinal function, retinal prostheses that function to fully or partially replace the native retina and/or other segments of the visual system, including the optic nerve, lateral geniculate nucleus, and visual cortex, have also been evaluated. Ultimately these devices all seek to restore vision by artificially activating the electrical responses in each of these locations. In the retina, a number of epiretinal, subretinal, and suprachoroidal prostheses have been developed, with varying levels of success. Furthermore, optogenetics, which utilizes gene transfer of light-sensitive proteins into retinal neurons, is another emerging avenue of study regarding vision loss. While an in-depth discussion of these techniques and devices is beyond the scope of this review, please refer to these recent publications by Yue et al.\(^{121}\), Fernandez and Normann\(^{122}\), and Lewis et al.\(^{123}\) for an all-encompassing assessment of the current progress in these fields.

Regardless of the type of ES utilized, whether SES, optic nerve stump ES, TcES, or WES, very few, if any, detrimental side effects have been reported for the subject during or after treatment. In general, it appears that ES treatment does in fact enhance the survival of neuronal retinal cells in various ophthalmic disease models through various mechanisms or, at the very least, does not hinder vision further. Moreover, the direct and indirect effects of ES on the retinal cells could also similarly affect transplanted cells in the ocular environment. We therefore propose a combination approach utilizing ES to enhance CT techniques to treat disease- or trauma-related visual deficits.

**APPLICATION OF ELECTRICAL STIMULATION TO ENHANCE CELL TRANSPLANTATION THERAPIES FOR RETINAL DISEASES**

Loss of vision not only affects the quality of life for the patient but also has societal implications in regard to their level of productivity and overall health care expenditure. Thus, it is essential to develop effective strategies for retinal cell survival, repair, and replacement for various neurodegenerative diseases affecting the retina. Fundamentally, our proposed combination of ES and CT techniques focuses on the use of electrical manipulation to control both native and transplanted stem cell behavior in order to bypass some of the common limitations associated with CT. For use in treating retinal degenerative diseases, ES-CT treatment addresses four main issues: native cell survival, transplanted cell survival, transplanted cell integration, and functional synapse formation/axon regeneration (Fig. 4).

The recent advances in the field of retinal ES imply that this technique could be used as a pretreatment to modulate retinal cell function, essentially priming the host environment for the introduction of transplanted cells. In order to elucidate the comprehensive mechanism of ES on the retina, a whole genome-wide expression profile of TcES-treated wild-type Brown Norway rats was performed using quantitative real-time PCR\(^{124}\). The results indicate that 490 genes were differentially expressed in TcES-treated rats compared to untreated rats 4 h after application and included changes in various genes associated with potential neuroprotective cell functions. For example, the authors observed a significant downregulation in the expression of various proapoptotic genes such as B-cell lymphoma 2-associated X (Bax) and members of the tumor necrosis factor (TNF) family. Furthermore, no negative effects on the structure and function of the retina were observed in the rats up to 35 h after TcES treatment. Ciavatta et al.\(^{125}\), on the other hand, focused their investigation on the specific expression of growth factors in the retinas of Royal College of Surgeons (RCS) rats, a widely used model of RP, after SES using a microphotodiode array. In doing so, they found a consistent, significant elevation in the expression of FGF2 (also known as bFGF), suggesting that this particular growth factor may participate in the local neuroprotection induced by ES.

Focusing on the effects of ES on retinal neuronal cells, Henrich-Noack et al.\(^{126}\) used an optic nerve crush animal model to test the effects of TcES treatment immediately after injury and on postinjury day 11. They found that compared to sham-treated controls, there was a higher percentage of surviving RGCs in the TcES group. TcES also delayed posttraumatic cell death significantly and decreased optic nerve crush-associated neuronal swelling as well as shrinkage, especially in RGCs. It is likely that this ES-mediated protection of the retinal neurons would apply to both endogenous and transplanted neuronal cells as it appears to be primarily related to the expression of neurotrophins, including brain-derived neurotrophic factor (BDNF), IGF-1, CNTF, etc., and injection of these factors appears to increase neuronal survival in several retinal injury models\(^{127,128}\).

Various effects have also been observed following ES treatment via the modulation of Müller and microglial cell changes. For example, it has been demonstrated that ES regulates neurotrophic factors and the levels of various enzymes in retinal Müller cells. In fact, in a study evaluating the neuroprotective effect of TcES on an animal model of ischemic retinal damage, Wang et al.\(^{129}\) quantified glutamine synthetase (GS) expression, which appears to be significantly increased following treatment. The morphology and function of the retina were also preserved in treated animals, indicating that the protection...
against ischemic insults mediated by TcES is possibly related to attenuated glutamate excitotoxicity in Müller cells. Sato et al.\textsuperscript{130} also found that after applying ES to cultured retinal Müller cells, the mRNA level of IGF-1 increased significantly and largely depended on the Ca\textsuperscript{2+} influx through L-type voltage-dependent calcium channels (L-VDCCs). Upregulation of IGF-1 was also found in optic nerve crush and optic nerve transection models after TcES\textsuperscript{131,132}. In a previous study, ES was observed to increase the mRNA and intracellular protein levels of...
BDNF in cultured retinal Müller cells, while its extracellular expression remained unchanged\textsuperscript{133}. Moreover, the L-VDCC blocker, nifedipine, has been shown to suppress this ES-induced increase in BDNF mRNA expression. These results indicate that ES of Müller cells could upregulate endogenous BDNF levels in the retina, and this upregulation may be dependent on L-VDCCs. In support of this theory, Zhou et al.\textsuperscript{134} found a positive regulatory effect of ES on the production of BDNF and CNTF in Müller cells, and also provided evidence that BDNF rather than CNTF may play a major role in the promotion of Müller cell-induced photoreceptor cell survival. Finally, in a recent proteomic study\textsuperscript{135}, TcES performed on wild-type adult Wistar rats was shown to significantly alter the expression of 25 proteins. These proteins appear to play various functions (e.g., cellular signaling, synaptic transmission, metabolism, immune function, and structural maintenance) and included several suspected retinal regeneration factors, such as epidermal growth factor receptor (EGFR), prohibitin, tenasin-X, etc. Interestingly, IGF-1, BDNF, and FGF-2 were surprisingly absent from this list, a discrepancy the authors believe is related to their experiments being conducted on wild-type retinas versus a degenerative model\textsuperscript{135}, similar to a previous study reporting changes in the transcriptome\textsuperscript{124}. Thus, it can be hypothesized that ES treatment may alter the secretion of these neurotrophic factors, resulting in a more balanced and less hostile environment.

In addition to changes in neuronal and Müller cells, ES has also been shown to influence retinal microglia. In fact, Zhou et al.\textsuperscript{134} found that ES can significantly decrease the number of activated microglia cells with ameboid shapes when cocultured with light-damaged 661W cells (light-reared cone-derived cells). This decrease was also associated with changes in the secretion of the proinflammatory cytokines interleukin-1β (IL-1β) and TNF-α by the microglial cells. In this same study, it was also apparent that ES treatment had no direct effect, positive or negative, on the survival of the photoreceptor cells themselves, but rather the functional changes are solely mediated by the effects of ES on surrounding microglia and Müller cells. Previous research also suggests that interactions between microglia and Müller glial cells in vivo may contribute to the overall effects of ES on the retina\textsuperscript{108}.

The expression of essential neurotrophic factors and altered Müller/microglial cell function not only appear to help keep the native retinal cells (and possibly the transplanted retinal stem cells) alive but also promote varying levels of axon growth\textsuperscript{36}. In this study, Goldberg et al. showed that increasing electrical activity and prolonging cellular depolarization potentiate the observed BDNF-induced axon growth via increasing cAMP levels. It is therefore possible that ES can enhance axonal function as well as regulate the immune environment in the native retinal cells. Similar effects on axon formation could also occur in the transplanted cells themselves.

The direct effects of ES performed before, during, or after CT on the transplanted cells have not been evaluated in the retina but have been investigated in studies performed using this type of combination therapy in other CNS-derived tissue injuries, such as brain and spinal cord traumas. For example, in a study using a spinal cord injury model in rats, transplanted BM-MSCs were subsequently subjected to ES, which resulted in significantly enhanced locomotor function, increased survival (31.3 ± 4.6\% compared to 26.7 ± 2.5\% in unstimulated transplants), differentiation, and integration of the transplanted cells as well as increased axonal regeneration, as determined by enhanced somatosensory-evoked potentials\textsuperscript{137}. It should also be noted that this previous study utilized an implantable ES device, which can be equated to similar devices used for retinal implantation. Furthermore, Matsumoto et al.\textsuperscript{138} have demonstrated that pretreating BM-MSCs with ES in vitro prior to transplantation resulted in an increase in neural markers at day 7 [nestin and paired box protein 6 (Pax6)] as well as day 14 [neurofilament heavy (NF-H) and microtubule-associated protein 2 (MAP2)] in culture. Furthermore, the expression of neurogenin 2 (Ngn2), a protein associated with neural differentiation, and β-catenin, a mediator of cell survival, proliferation, and differentiation, was also increased on culture day 7 in the ES-treated cells. When these 7-day-old stimulated cells were transplanted into C57BL/6 mice with traumatic brain injury, the authors observed a higher percentage of transplanted cells expressing neural markers after stimulation along with enhanced neuronal differentiation and significantly improved motor function, as highlighted by rotarod (performed on days 14 and 28) and beam walking (performed on day 28) tests (p < 0.01 in both compared to the control animals). The mammalian retina also expresses both Ngn2\textsuperscript{139} and β-catenin\textsuperscript{140}. Ngn2 appears to regulate the expression of the atonal homolog 5 (ATH5) and, thus, the downstream expression of the β3 subunit of a neuronal nicotinic acetylcholine receptor\textsuperscript{141}, which is a specific marker of RGC specification during retinogenesis\textsuperscript{142}. β-Catenin signaling, on the other hand, plays an essential role in modulating the effects of various growth factors and cytokines during retinal regeneration after injury\textsuperscript{143,144} as well as during development, affecting the expression of a number of genes involved in chromatin organization, neurogenesis, and cell motion/migration\textsuperscript{145}. It is, therefore, possible that treating cells with ES prior to or during retinal transplantation could also affect the expression of these genes in a manner that would aid survival, differentiation, and function after CT.

Similar to these results concerning spinal cord and traumatic brain injury, ES-enhanced CT has also been observed during muscle reinnervation after sciatic injury.
using transplanted neurons and myocardial regeneration following ischemic heart failure, the latter of which appears to occur via stimulation and production of exosomes containing cardioprotective molecules. Notably, exosomes are also utilized for cell–cell communication in the normal and diseased retina and confer different biological effects depending on their host cell. For example, using a laser-induced choroidal neovascularization model, Kurimoto et al. demonstrated that retinal astrocytes produce exosomes that contain factors that suppress vessel leakage and inhibit neovascularization, while exosomes released from the RPE do not mediate these changes. In fact, it is possible that exosomes may play a critical role in ES-induced changes in chorioretinal blood flow observed after treatment. In this study by Kurimoto et al., which investigated the chorioretinal blood flow in 10 healthy subjects before and after TcES in different retinal areas using laser speckle flowgraphy, TcES was shown to induce an increase in chorioretinal blood flow in the area around the macula and midway between the optic disc and macula, but not around the optic disc itself. Indeed, blood flow rapidly increased in the first 30 min after TcES, peaked at 24 h, and decreased gradually by 40 h after treatment. This is consistent with the observed increase in IGF-1, a known effector of vasodilation, in retinal Müller cells, which are themselves known to regulate retinal blood flow via the secretion of growth factors. While the full mechanism underlying how TcES leads to this increase in chorioretinal blood flow remains unclear, it is possible that endosomes play a significant role. It also seems plausible that treatment with ES may not only alter the contents of these exosomes but may also induce their production in both the transplanted cells as well as the remaining retinal cells. These changes could have a significant effect on cell communication and the transfer of materials (e.g., proteins, mRNA, miRNA, etc.), leading to greater integration of the exogenous cells, protection of the surviving endogenous cells, and enhanced visual function. Thus, additional research investigating exosome function after ES-CT treatment is warranted.

Optimization of ES-CT combination therapy in future studies should focus on the type and timing of ES (e.g., as a pretreatment, simultaneous, or post-CT) as well as the ideal cell type for transplantation under these conditions. Additional investigations should also be performed to evaluate other experimental and evaluation parameters.

CONCLUSION

The eye has various characteristics that make it an ideal organ system to study regeneration, including unique immune properties, isolation from other organs, easy surgical accessibility, well-understood anatomy and physiology, and convenience of imaging and functional monitoring. Further, while vision is one of our most important senses, it is not essential to life, permitting continued study of the tissue following complications and/ or failed treatment. The eye is also a paired structure in vertebrates, which allows comparison to the contralateral eye during treatment in a single organism.

The retina is an essential component of the visual axis and is also susceptible to a number of degenerative diseases involving photoreceptor, RGC, and/or RPE cell death or dysfunction. It is imperative that effective treatment options to replace and stimulate these cells be developed for clinical use. While both ES and CT have beneficial effects when used as individual courses of treatment, studies in a number of other CNS tissues suggest that they may have additive advantages when ES is used to augment CT.

In the present review, we have outlined the basic concepts, mechanisms, and limitations of CT as well as a brief history of ES in the hopes that future research into their optimization and combined use will enhance their effectiveness in treating retinal degenerative diseases. The current literature describing ES-CT combination methods in other cellular contexts provides an excellent foundation for future investigations in the retina. Ongoing research in this field will be paramount to the prevention and cure of retinal degenerative diseases.

ACKNOWLEDGMENTS: This work was supported by a grant from the Seed Funding Program for Basic Research at the University of Hong Kong, as well as funding from Neurotech Ltd. The authors declare no conflicts of interest.
REFERENCES


36. Bernardos RL, Barthel LK, Meyers JR, Raymond PA. Late-stage neuronal progenitors in the retina are radial


55. Wiley LA, Burnight ER, Songstad AE, Drack AV, Mullins RF, Stone EM, Tucker BA. Patient-specific induced pluripotent stem cells (iPSCs) for the study and treatment of retinal degenerative diseases. Prog Retin Eye Res. 2015;44:15–35.


82. Lamba DA, Karl MO, Ware CB, Reh TA. Efficient generation of retinal progenitor cells from human embryonic stem cells. Proc Natl Acad Sci USA 2006;103(34):12769–74.


